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A B S T R A C T
Twenty Apolipoprotein A-I (ApoA-I) variants are responsible for a systemic hereditary amyloidosis in which
protein ﬁbrils can accumulate in diﬀerent organs, leading to their failure. Several ApoA-I amyloidogenic mu-
tations are also associated with hypoalphalipoproteinemia, low ApoA-I and high-density lipoprotein (HDL)-
cholesterol plasma levels; however, subjects aﬀected by ApoA-I-related amyloidosis do not show a higher risk of
cardiovascular diseases (CVD). The structural features, the lipid binding properties and the functionality of four
ApoA-I amyloidogenic variants were therefore inspected in order to clarify the paradox observed in the clinical
phenotype of the aﬀected subjects.
Our results show that ApoA-I amyloidogenic variants are characterized by a diﬀerent oligomerization pattern
and that the position of the mutation in the ApoA-I sequence aﬀects the molecular structure of the formed HDL
particles. Although lipidation increases ApoA-I proteins stability, all the amyloidogenic variants analyzed show a
lower aﬃnity for lipids, both in vitro and in ex vivo mouse serum. Interestingly, the lower eﬃciency at forming
HDL particles is compensated by a higher eﬃciency at catalysing cholesterol eﬄux from macrophages.
The decreased aﬃnity of ApoA-I amyloidogenic variants for lipids, together with the increased eﬃciency in
the cholesterol eﬄux process, could explain why, despite the unfavourable lipid proﬁle, patients aﬀected by
ApoA-I related amyloidosis do not show a higher CVD risk.
1. Introduction
Apolipoprotein A-I (ApoA-I) hereditary systemic amyloidosis is a
rare, autosomal dominant, late onset disease caused by speciﬁc muta-
tions in the APOA1 gene [1]. The disease is characterized by the pro-
gressive accumulation of protein ﬁbrils in the aﬀected organs, such as
heart, liver, kidneys, nerves, ovaries or testes, eventually leading to
organ failure [2–4].
ApoA-I represents the major protein component of high density li-
poprotein (HDL) and plays a fundamental role in lipid metabolism, both
in delivering cholesterol to steroidogenic tissues and in transporting it
from the periphery to the liver for catabolism in the process known as
reverse cholesterol transport (RCT) [5]. To exert its functions in the
RCT, lipid free/poor ApoA-I interacts with the ATP binding cassette A1
(ABCA1) in peripheral tissues to promote the eﬄux of cholesterol from
macrophages, thus forming nascent HDL particles. These particles be-
come mature after the esteriﬁcation of cholesterol through le-
cithin:cholesterol acyltransferase (LCAT). Maturation of spherical HDL
is a necessary step to allow the interaction of ApoA-I with the scavenger
receptor class B type 1 (SRB1), present on the hepatocytes, to release
cholesterol [6]. Therefore, ApoA-I plays an anti-atherogenic role, pro-
tecting against cardiovascular diseases (CVD) [7,8].
ApoA-I is mainly associated to lipids but it can also be found in a
lipid-free state (5–10%) [9]. In healthy subjects, serum lipid free ApoA-I
can either form new HDL particles, or bind to existing ones, or can be
catabolized [5,10]. In the presence of one of the twenty amyloidogenic
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mutations identiﬁed so far, lipid-free ApoA-I can also face an alter-
native fate, where misfolding of the protein leads to aggregation in
amyloid ﬁbrils [11,12]. Although the molecular mechanism of ﬁbril
formation and accumulation of ApoA-I amyloidogenic variants has been
extensively studied [13–18], it remains not fully understood. Interest-
ingly, the localization of the mutations in the ApoA-I protein sequence
seems to direct protein aggregation in speciﬁc organs. Indeed, amy-
loidogenic mutations in the residues 1–75 of the protein lead mostly to
hepatic, renal, and testis amyloidosis, whereas mutations in residues
173 to 178 mainly lead to cardiac, laryngeal, and cutaneous protein
accumulation [2,3]. The determinants of this tissue-speciﬁcity currently
represent a challenge in the study of ApoA-I-related amyloidosis.
Some ApoA-I amyloidogenic variants have been found associated
with hypoalphalipoproteinemia and with a reduction of plasma ApoA-I
levels. In subjects carrying the substitution of a glycine in position 26
with an arginine (G26R variant), the lower plasma levels of HDL and
ApoA-I were found to be a consequence of an accelerated metabolism of
both the mutated and the native protein [19]. In two clinical studies,
involving 30 and 253 aﬀected individuals respectively, carriers of the
amyloidogenic variant with leucine to proline substitution at position
75 (L75P variant) displayed lower levels of plasma ApoA-I, decreased
levels of HDL (32% decrease relative to healthy subject) and signiﬁcant
reduction in HDL-cholesterol [4,20]. Similarly, a clinical case study
conducted on a subject carrying the ApoA-I variant with a leucine to
serine substitution in position 174 (L174S variant), showed a signiﬁcant
reduction of serum ApoA-I and HDL- and total cholesterol compared to
the healthy relatives [21]. Interestingly, despite this unfavourable lipid
proﬁle, patients aﬀected by ApoA-I-related systemic amyloidosis do not
show a signiﬁcant higher risk of cardiovascular diseases, as recently
demonstrated in a clinical study on 131 carriers of the L75P variant. In
this study, Muiesan and co-workers found that L75P carriers do not
show any structural and functional vascular abnormality, allowing
them to hypothesize that the low levels of HDL and HDL-cholesterol
observed in the aﬀected subjects is balanced by a still unclear “pro-
tective” mechanism [22].
In order to shed light on the structural and functional disparities
among the diﬀerent variants, we focused on four ApoA-I amyloidogenic
variants, of which two accumulate preferentially in the liver and kidney
(G26R and L75P), and two are known to form ﬁbrils preferentially in
heart and skin (L174S and L178H), as well as the wild-type protein
[23–26]. These amyloidogenic variants are also representative of the
two hot-spot mutation sites present in the crystal structure of the C-
terminal truncated version of the protein [27,28]. For the ﬁrst time, our
ﬁndings deﬁne a connection between the alterations in the protein
structure and function and the clinical phenotype.
2. Materials and methods
2.1. Production of recombinant ApoA-I amyloidogenic variants
ApoA-I amyloidogenic variants, as well as the WT protein, were
produced in a bacterial expression system consisting of ApoA-I ex-
pressing pEXP-5 plasmid in Escherichia coli strain BL21(DE3) pLysS
(Invitrogen), as previously described [14,29] with some modiﬁcations.
Primer-directed PCR mutagenesis was used to introduce the G26R,
L75P, L174S and L178H mutations and the constructs were veriﬁed by
dideoxy automated ﬂuorescent sequencing (GATC Biotech). Bacterial
cells were transformed with recombinant plasmids and cultivated in
Luria Bertani medium at 37 °C, for the production of WT and L178H
variant, in NZYM with 0.2% glucose at 37 °C or 30 °C, for the produc-
tion of G26R and L174S variants respectively, and in EnPresso® B
medium (BioSilta), at 30 °C, for the production of L75P variant. All the
media were supplemented with 50 μg/ml ampicillin and 34 μg/ml
chloramphenicol. Protein expression was induced for 4 h following the
addition of 1 mM isopropyl-beta-thiogalactopyranoside (Thermo). His-
tagged ApoA-I variants were puriﬁed from bacterial cell lysate by
immobilized metal aﬃnity chromatography (His-Trap-Nickel-chelating
columns, GE Healthcare) under denaturing conditions (3 M guanidine
in phosphate-buﬀered saline (PBS), pH 7.4). Following binding, an ex-
tensive wash with 40 mM imidazole in PBS was performed and bound
proteins were then eluted with 500 mM imidazole in PBS. Imidazole
was removed from protein samples by using desalting columns (GE
Healthcare) equilibrated with PBS, pH 7.4, and tobacco etch virus
(TEV) protease was employed overnight at 4 °C to remove the His-tag
from protein samples. At the end of the incubation, a second Ni2+-
column step was employed in order purify the cleaved ApoA-I from TEV
protease and the His-tag, with the latter two being retained on the
column. The ﬂow-through, containing cleaved ApoA-I variants, was
desalted in PBS, pH 7.4, concentrated with 10 kDa cut-oﬀ Amicon Ultra
centrifugal ﬁlters (Millipore) and stored at 4 °C prior to use. Protein
concentration was determined by Nanodrop and protein purity was
conﬁrmed by sodium dodecyl sulfate (SDS)-polyacrylamide gel elec-
trophoresis with Coomassie blue staining.
2.2. Lipidation of ApoA-I amyloidogenic variants
2.2.1. DMPC lipoparticles preparation
Lyophilized DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine;
Avanti Polar Lipids) was dissolved in 3:1 chloroform:methanol and the
solvent was completely evaporated by overnight incubation under a
stream of nitrogen gas. DMPC was then dissolved in PBS or McIlvaine
buﬀer (165 mM Na2HPO4, 17.6 mM citrate, pH 7.0) and the lipid sus-
pension was extruded through a 100-nm polycarbonate membrane
using the LiposoFast system (Avestin) to create multilamellar vesicles.
The reconstituted HDL particles (rHDLs) were produced by incubating
the recombinant proteins with multilamellar DMPC particles at a 1:100
protein to lipid molar ratio and a protein concentration of 1 mg/ml at
24 °C, the transition temperature for DMPC, for 96 h.
2.2.2. POPC lipoparticles preparation
Lyophilized POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line, Avanti Polar Lipids) was dissolved in 3:1 chloroform:methanol and
the solvent evaporated by overnight incubation under a stream of ni-
trogen gas. POPC was dissolved in PBS and lipoparticles were generated
by using the cholate dialysis method. Brieﬂy, POPC lipoparticles were
produced by incubating ApoA-I proteins with a mixture of 1:2
POPC:sodium deoxycolate at a 1:80 protein to lipid molar ratio at a
0.5 mg/ml protein concentration. Mixtures were incubated at 37 °C for
1 h and then dialysed against PBS for 72 h.
At the end of the incubation, rHDLs (both DMPC and POPC parti-
cles) were analyzed by Blue Native PAGE by using the NativePAGE Bis-
Tris Gel System 4–16% (Invitrogen) according to the manufacturer's
instructions.
2.2.3. Lipid clearance assay
Lipid clearance was monitored by monitoring the decrease in the
absorbance of the multilamellar vesicles and protein mixture at 325 nm
every 10 s for 10 min, as previously described [29].
2.2.4. Formation of rHDL in vitro
Amyloidogenic ApoA-I variants, as well as the WT protein, were
mixed with DMPC multilamellar vesicles (1:100 protein to lipid molar
ratio) at the concentration of 0.4 mg/ml and incubated at 24 °C, in
agitation. Samples were taken at 0, 1, 3, 6, 9, 12, 24, 96 h and stored at
−80 °C in the presence of 10% sucrose prior the Blue Native PAGE
analysis or analyzed by Synchrotron Radiation Circular Dichroism
(SRCD) directly at the end of each incubation time.
2.2.5. Formation of rHDL ex vivo
Male C57BL/6 mice were purchased from Taconic (Ry, Denmark)
and were used at the age of 8 weeks. The protocol for the rHDL for-
mation ex vivo was adapted from [29]. Brieﬂy, blood samples were
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collected by cardiac puncture and serum samples (200 μl) were mixed
with ApoA-I amyloidogenic variants and the WT protein at the con-
centration of 0.75 mg/ml. The mixtures were incubated at 37 °C, in
agitation, samples were taken after 0, 0.5, 1, 3, 6, 9, 24 and 48 h and
stored at −80 °C. The samples were separated by NativePAGE Bis-Tris
Gels System 4–16% (Invitrogen), transferred to PVDF membranes, and
probed with anti-human ApoA-I antibodies (ab64308, Abcam). Detec-
tion was performed by using HRP-conjugated secondary antibodies (GE
Healthcare) and a chemi-luminescence detection substrate (Super-
Signal® West Femto, Thermo Scientiﬁc). Blots were imaged using the
Odyssey Fc system (LI-COR).
The animal procedures were approved by the Malmö/Lund
Committee for Animal Experiment Ethics.
2.3. Dynamic light scattering
Volume-size distribution of lipid-free and -bound proteins was de-
termined by using a Malvern Zetasizer Nano (Malvern Instruments
Limited), using plastic cuvettes with a ﬁnal volume of 60 μL. Protein
samples were diluted at 0.5 mg/ml in McIlvaine buﬀer and centrifuged
at 14000 rpm for 30 min. Data was processed using Zetasizer family
software version 7.11 (Malvern Instruments Limited). All quality in-
formation was reported as good and therefore accepted.
2.4. Synchrotron radiation circular dichroism
SRCD experiments were performed using a nitrogen-ﬂushed Module
B end-station spectrophotometer at B23 Synchrotron Radiation CD
Beamline at the Diamond Light Source, Oxfordshire, UK [30,31]. The
data were analyzed using CDApps [32] and the estimation of secondary
structure was performed using the CONTINLL algorithm [33] with re-
ference data SP 43, between 190 and 260 nm.
2.4.1. Concentration dependence studies
Lipid free (LF) ApoA-I protein samples were dialysed against
McIlvaine buﬀer in order to minimize the noise at wavelengths below
200 nm. Protein samples were diluted at 0.1, 0.5 and 1.5 mg/ml, loaded
into quartz cuvettes (0.1, 0.2 or 0.5 mm path lengths, depending on
protein concentration) and the spectra acquired at 25 °C in the far-UV
range 185–260 nm, with a 1 nm wavelength increment. All the spectra
were corrected subtracting the background signal of the buﬀer.
2.4.2. rHDL particles analysis
rHDL particles (lipid-bound (LB) samples) were produced in
McIlvaine buﬀer and analyzed by SRCD at 0.5 mg/ml in a 0.2 nm
quartz cuvette. Spectra were acquired at 24 °C in the far-UV range
185–260 nm, with a 1 nm wavelength increment. All the spectra were
corrected subtracting the background signal of DMPC vesicles diluted in
McIlvain buﬀer.
2.4.3. Thermal stability analyses of LB proteins
LB samples were diluted in McIlvaine buﬀer at 0.5 mg/ml and
placed in a 0.2 mm quartz cuvette. SRCD spectra were collected in
25–85 °C range, with a 10 °C increment. The analysis of the secondary
structure during the thermal denaturation was performed by using the
CONTINLL algorithm with reference data SP 43, between 190 and
260 nm.
2.5. Complementary proteolysis experiments and mass spectrometry
analysis
LB and LF ApoA-I proteins (0.3 mg/ml) were treated with trypsin,
chymotrypsin, endoproteinase Glu-C and subtilisin in PBS, pH 7.4. Each
enzyme:substrate (E:S) ratio was optimized for each proteolytic probe
on the LF and LB WT ApoA-I and the same amount of enzyme was
employed to digest all ApoA-I variants. For the experiments on LF
proteins, the E:S employed were 1:8000 for chymotrypsin and trypsin,
1:10,000 for Glu-C and subtilisin, whereas for LB samples the E:S were
1:3000 for chymotrypsin, 1:100 for trypsin, 1:200 for Glu-C and 1:1000
for subtilisin. Digestions were monitored on a time-course basis by
sampling the reaction products at diﬀerent times (15 and 30 min, or 30
and 60 min) and blocking enzyme digestions with 2% triﬂuoroacetic
acid (TFA). Peptide mixtures from the diﬀerent proteolysis experiments
were analyzed by liquid chromatography-mass spectrometry (LC-MS)
onto a Quattro Micro LC-MS system (Micromass, Waters) coupled with
a 1100 HPLC (Agilent Technologies, Palo Alto, CA). Peptides fractio-
nations were carried out by reverse-phase HPLC on a Phenomenex
Jupiter C18 column (250 mm× 2.1 mm, 300 Å pore size) and eluted
by using a step gradient from 5% to 60% of solvent B (5% formic acid
and 0.05% TFA in acetonitrile) over 60 min and from 60% to 95% in
5 min (solvent A 5% formic acid and 0.05% TFA in water), at ﬂow rate
of 200 μl/min directly introduced in mass spectrometers ESI source.
Horse heart myoglobin (average molecular mass 16,951.5 Da) was used
as standard for the instrument calibration at 5 scans/s.
2.6. Cholesterol eﬄux
Cholesterol eﬄux assay was adapted from [29,34,35] with some
modiﬁcations. J774 macrophages (ATCC, TIB-67) were plated into 24-
well cell culture dishes at 100,000 cells/well in RPMI 1640 (Gibco)
supplemented with 10% FBS and 50 μg/ml gentamicin. 24 h after
plating, the medium was replaced with RPMI 1640 containing 5% FBS,
4 μCi/ml 3H-cholesterol (Perkin Elmer), 2 μg/ml ACAT inhibitor
(Sandoz 58–035, Sigma) and 50 μg/ml gentamicin. After a further 24 h
incubation, the medium was replaced with RPMI 1640 supplemented
with 0.2% BSA (low free fatty acids and low endotoxin, Sigma), 2 μg/ml
ACAT inhibitor, 0.3 mM Cpt-cAMP (Abcam) and 50 μg/ml gentamicin
for 18 h. At the end of incubation, cells were washed twice with RPMI
1640 and then triplicate wells were treated with the amyloidogenic
variants or the WT protein, both in their LF or LB form (either DMPC- or
POPC-ApoA-I particles), in RPMI 1640 supplemented with 0.2% BSA, at
the indicated concentrations for 2, 4 or 24 h. Cholesterol eﬄux was
measured in the media by centrifugation at 4000 ×g for 5 min at room
temperature and transfer of 100 μl supernatant to a scintillation vial.
5 ml of scintillation ﬂuid was added to each sample before scintillation
counting was performed (Perkin Elmer). The measure of the total 3H-
cholesterol in the cells was obtained by solubilizing the incubated cells,
in triplicate, with 1% sodium deoxycholate and scintillation counting of
the collected lysates. Eﬄux for each treatment was calculated as the
percentage of the total 3H-cholesterol. Non-speciﬁc background eﬄux
was measured in triplicate for each time point, in each experiment, and
the eﬄux for each treatment subtracted for this value.
2.7. Statistical analysis
Data shown are the mean ± SD or± SEM, as indicated. Analysis
was performed by one-way ANOVA with Tukey's post hoc test, using the
GraphPad software.
3. Results
3.1. ApoA-I amyloidogenic variants' secondary structure is inﬂuenced by
protein concentration and association with lipids
To explore the structural disparities among the ApoA-I amyloido-
genic variants, protein samples were analyzed in their lipid free (LF)
and lipid bound (LB) states, by using several biophysical approaches
(Fig. 1).
LF proteins were analyzed by Blue Native Gel electrophoresis and
dynamic light scattering (DLS) (Fig. 1a). As shown in the Native Gel, all
proteins presented a pattern composed of two species, a less abundant
one, approximately of 7.8 nm, and a predominant one with a smaller
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size. In particular, in the case of L75P and L178H variants the 7.8 nm
species was more abundant compared to the WT. Interestingly, the
G26R and L174S variants presented three other species of higher sizes
(8.1, 9 and 12.2 nm, approximately), particularly evident in the case of
G26R variant. However, for G26R variant, the estimated averaged hy-
drodynamic diameter, obtained by DLS, was found to be very similar to
that determined for the native protein (12.9 and 12.2 nm for WT and
G26R, respectively), whereas the other variants showed signiﬁcantly
lower diameters (8.5, 9.0 and 10.2 nm for L75P, L174S and L178H,
respectively). Although these results are in good agreement with those
previously obtained on the native and L174S variant [17], the hydro-
dynamic diameter observed here for the lipid-free L75P variant is sig-
niﬁcantly smaller.
Then, reconstituted HDL particles (herein referred to as rHDLs or
LB) were produced by incubating the recombinant proteins with mul-
tilamellar DMPC particles at a 1:100 protein to lipid molar ratio and a
protein concentration of 0.5 mg/ml at 24 °C, which is the transition
temperature for DMPC. After 4 days of incubation, the rHDLs were
analyzed by native gel electrophoresis (Fig. 1b). It is worth to notice
that, although the Stokes diameter of all the rHDLs was found to be
approximately 10 nm, the particles formed by the L174S and L178H
variants showed a slightly smaller size with respect to those produced
by G26R and L75P variants as well as the WT protein, suggesting that
the position of the amyloidogenic mutation in the ApoA-I sequence
could alter the molecular structure of the formed rHDLs. These results
are in good agreement with those obtained by DLS. Indeed, as shown in
Fig. 1b, right panel, the hydrodynamic volume calculated for the L174S
and L178H variants was signiﬁcantly smaller (10.4 and 10.2 nm for
L174S and L178H, respectively) compared to that calculated for the WT
protein and the other ApoA-I variants (11.3, 10.8 and 11.1 nm for WT,
G26R and L75P, respectively).
Then, the secondary structure of all ApoA-I variants was in-
vestigated by far-UV synchrotron radiation circular dichroism (SRCD)
spectroscopy (Fig. 1c–d). SRCD spectroscopy was chosen as the high
photon ﬂux that characterize the synchrotron light enables measure-
ments of proteins in the presence of highly interfering molecules such as
phospholipids. The decrease of the noise in the 180–200 nm spectral
range made then possible the estimation of the secondary structure
content of the ApoA-I proteins in their lipid bound state.
First, the impact of protein oligomerization on the proteins'
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Fig. 1. ApoA-I variants' secondary structure depends on protein concentration and lipidation state. Blue Native gels and DLS analysis of (a) lipid free (LF) or (b) lipid bound (LB) ApoA-I
amyloidogenic variants. Gels were loaded with 5 μg of each protein. The LB proteins were obtained by incubating the ApoA-I variants, as well as the WT protein, with DMPC multilamellar
vesicles at 24 °C for 96 h. Data shown represents the contribution of the experimental data with a line at the median (n= 3). Signiﬁcance is calculated according to one-way ANOVA
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groups as shown with respect to L75P variant). (c) SRCD spectra of LF proteins at diﬀerent concentrations (0.1, 0.5 and 1.5 mg/ml) and LB proteins at 0.5 mg/ml. (d) Secondary structure
estimation of ApoA-I amyloidogenic variants, obtained by analysing the spectra in (c) with the CONTINLL algorithm. Data shown are the mean ± SD (n = 3 for LF 0.1 mg/ml and n= 2
for the other protein samples). Signiﬁcance is calculated according to two-way ANOVA. Upper panel, *p < 0.05, **p < 0.005, ****p < 0.0001 for groups as shown with respect to the
WT protein, ##p < 0.005, ###p < 0.00, ####p < 0.0001 for groups as shown with respect to G26R variant, §§§p < 0.001 for groups as shown with respect to L75P variant. Lower
panel, *p < 0.05, ***p < 0.001, ****p < 0.0001 for groups as shown with respect 0.1 mg/ml, #p < 0.05, ##p < 0.005, ###p < 0.00, ####p < 0.0001 for groups as shown with
respect to LF 0.5 mg/ml, §p < 0.05, §§p < 0.005, §§§§p < 0.0001 for groups as shown with respect to 1.5 mg/ml.
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secondary structure was analyzed as a function of protein concentra-
tion. In Fig. 1c, representative spectra of the ApoA-I variants at diﬀerent
concentration (0.1, 0.5 and 1.5 mg/ml, representing diﬀerent oligo-
meric states of the ApoA-I proteins) and in their lipid bound state
(0.5 mg/ml) are reported. As shown in Fig. 1d, the increase of protein
concentration led to an increase in the α-helical content with a con-
comitant reduction in turns and unordered content. This trend was
particularly evident for the WT and the G26R variant in which the α-
helical content increased from about 50% at 0.1 mg/ml to about 60% at
1.5 mg/ml. The L174S and L178H variants showed a similar behavior
but the major increase in the α-helical content occurred when the
protein concentration was increased from 0.5 mg/ml to 1.5 mg/ml
(from about 48% at 0.5 mg/ml to about 54% at 1.5 mg/ml). Interest-
ingly, the L75P variant (Fig. 1c–d,) did not follow the same trend, as the
α-helical content for this variant remained approximately 40%, and the
increase in protein concentration led to a higher β-strand content (from
10 to 15%). These results suggest that, even though ApoA-I con-
formation and oligomeric state are generally dependent on protein
concentration, the extent of structural rearrangements might be af-
fected by the position of the mutation in the protein sequence.
Then, the eﬀects of lipidation on ApoA-I variants' secondary struc-
ture was evaluated. In their lipid bound state (Fig. 1c–d, right panels),
all the proteins acquired a predominant α-helical conformation. No-
tably, although the L75P variant showed the lower α-helical content in
its lipid free state, the HDL-bound L75P variant acquired a secondary
structure conformation very close to that of the WT protein. L174S- and
L178H-HDLs also showed an interesting behavior since they were
characterized by a higher helicity (70% and 76%, respectively) com-
pared to the G26R and L75P variants, and the WT protein (all having
about 65% α-helical content), as well as a decrease in unordered and
turns. The diﬀerences observed in the secondary structure contents and,
in particular, in the α-helix content, could explain the diﬀerence in the
size of the lipoparticles prepared with the diﬀerent amyloidogenic
variants.
3.2. Lipidation increases the stability of the ApoA-I amyloidogenic variants
The thermal stability of LB ApoA-I variants, as well as the secondary
structure rearrangements during the thermal unfolding process, were
evaluated by SRCD spectroscopy (Fig. 2).
Analyses were performed by collecting the spectra in the 25–85 °C
range, with a 10 °C increment. Changes in protein secondary structure
(Fig. 2a–b) revealed that all ApoA-I variants, as well as the WT protein,
had high thermal stability. Indeed, the decrease of the α-helical struc-
ture, with the concomitant increase of the other secondary structure
elements, was found to be a gradual process, reaching a minimum at
around 75–85 °C. Importantly, at the end of the denaturation process
(85 °C), the decrease in the α-helical content, along with the con-
comitant increase in the β and unordered structures, was more ex-
tensive in the case of the amyloidogenic variants than in the WT pro-
tein. Indeed, the α-helical content dropped to around 20% in the case of
the four amyloidogenic variants whereas it decreased only 34% in the
native protein, where the contribution of the other secondary structure
elements remained relatively low (19% β or turn, and 25% unordered
in WT protein vs 30% β or turn, and about 25% unordered in the
amyloidogenic variants). It is also worth to notice that the G26R and
L75P were the most sensitive to the thermal unfolding since, in these
variants, signiﬁcant decrease in the α-helical content occurred at a
lower temperature (45 °C for G26R and L75P vs 55 °C for both the other
two variants and the WT protein).
Then, a complementary proteolysis approach coupled to mass
spectrometry was employed to map the exposed and ﬂexible regions in
both LF and LB ApoA-I proteins, thus allowing the detection of con-
formational alterations in the diﬀerent ApoA-I variants (Fig. 3). Com-
plementary proteolysis experiments were carried out in strictly con-
trolled conditions (i.e. E:S ratios and time of hydrolysis) and cleavage
sites were determined by mass-spectroscopic identiﬁcation of the gen-
erated peptides [36,37].
The results of the limited proteolysis experiments on LF proteins are
shown in Fig. 3a and reported in Tables S1–S4 in Supplementary ma-
terials. All LF proteins showed a similar global accessibility and, in
particular, all proteins presented several proteolytic cleavage sites at
the N-terminus (region 1–57), between the residues 131–136 and at the
C-terminus from residue 188 to residue 223. However, at an equal E:S
ratio, all ApoA-I variants became more susceptible to proteolysis than
the WT protein, as demonstrated by the higher number of cleavage sites
identiﬁed. The central region spanning residues 131–153 was more
accessible to proteases in the variants than in the WT protein, for which
the region sensitive to the proteolysis involved residues 131–136.
Speciﬁc proteolytic cleavages were also observed at positions close to
the mutation sites. Indeed, in the G26R mutant digestion occurred at
R27, immediately downstream the mutation spot, whereas in L174S
and L178H species, additional enzymatic cleavages occurring at Y166/
R173 and L159/R173, respectively, indicated the presence of local
perturbation in protein conformation induced by the amino acid
changes.
The proteolytic patterns of LB proteins are shown in Fig. 3b. A large
reduction in the number of cleavage sites was clearly observed in all
HDL-bound ApoA-I proteins compared to LF suggesting that the pre-
sence of lipids increased the overall proteins compactness and stability.
The largest protective eﬀect caused by the lipidation occurred in the
central region at the C-terminus for the variants as well as for the WT
ApoA-I. Speciﬁc protease accessibility was still observed for the G26R
variant at R26 and R27, and for the L174S and L178H variants at R173,
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Fig. 2. Thermal stability of ApoA-I amyloidogenic variants. (a) SRCD spectra and (b) secondary structure estimation of LB proteins during thermal unfolding. Data shown are the
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conﬁrming a local destabilization induced by the presence of mutations.
An opposite trend was observed at the N-terminus of the amyloidogenic
proteins where, in general, the accessibility to this region was partially
reduced compared to the LF proteins. In contrast, the N-terminus of the
WT ApoA-I protein became more accessible the LB form.
3.3. The lipid binding activity is aﬀected in the amyloidogenic ApoA-I
variants
A lipid-binding assay was then performed to study the functional
properties of the ApoA-I amyloidogenic variants, as ApoA-I exerts its
main functional role when bound to phospholipids and cholesterol.
The lipid-binding capacity was determined by a lipid clearance
assay (Fig. 4), in which the decrease of the absorbance at 325 nm due to
the clearance of multilamellar DMPC vesicles by the LF proteins is
measured. The rate of DMPC binding was expressed as t1/2, calculated
by ﬁtting the experimental data with a one-way decay curve of non-
linear regression (Fig. 4a). Interestingly, the kinetics of lipid binding
was slower for all the amyloidogenic variants analyzed, with a 3-fold
increase in the t1/2 for G26R and L75P variants and a 7-fold and 4-fold
increase for the L174S and L178H variants, respectively, compared to
WT (Fig. 4b).
Then, the formation of reconstituted HDL particles was followed
over time. Recombinant proteins were incubated at 24 °C with multi-
lamellar DMPC vesicles (1:100 protein to lipid molar ratio) for the in-
dicated length of time and analyzed by Native PAGE (Fig. 5a) and SRCD
spectroscopy (Fig. 5b).
As shown in Fig. 5a, all the amyloidogenic ApoA-I variants were
able to form similar intermediate structures as the WT protein, with the
formation of rHDL particles of approximately 10 nm diameter already
after 24 h of incubation. Although the formation of the rHDL particles
was a gradual, time-dependent process, the conformational changes in
the secondary structure (Fig. 5b) were found to be very fast. In parti-
cular, L178H and the WT protein underwent a signiﬁcant conforma-
tional transition as soon as they were mixed with DMPC vesicles (time 0
and 0.5 in Fig. 5b), reaching a value of α-helical content very similar to
that of the fully formed rHDL particles and with minor secondary
structure's rearrangements during the process. The other amyloidogenic
variants, instead, showed a more gradual structural rearrangement,
reaching a value of helicity close to that of the ﬁnal stage only upon 1 h
incubation at 24 °C.
The formation of lipoparticles was also followed in a more physio-
logical environment. For this purpose, proteins were incubated in
mouse serum at 37 °C (Fig. 6).
The formation of recombinant HDL was monitored over time by
western blot analysis using antibodies directed towards human ApoA-I.
The incubation of ApoA-I in mouse serum appeared to lead to the in-
corporation of the human protein in existing mouse HDL particles, as
antibodies directed towards either human or mouse ApoA-I coincided in
western blot analyses (data not shown). WT-ApoA-I was able to eﬃ-
ciently form HDL already after 0.5 h of incubation, with no apparent
immuno-signal associated with LF protein after 2 h of incubation.
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Interestingly, all the amyloidogenic variants showed a reduced eﬃ-
ciency to form HDL in mouse serum with LF protein observed also after
24 h of incubation.
The decreased aﬃnity of the amyloidogenic variants for the lipids in
this physiological-like environment, along with an enhanced metabo-
lism of the lipid free protein, may explain the lower serum levels of the
ApoA-I proteins (both variant and the WT) found in patients aﬀected by
ApoA-I related amyloidosis [19–23].
3.4. ApoA-I amyloidogenic variants have improved eﬃciency at catalysing
cholesterol eﬄux
As the main function of lipidated ApoA-I is to eﬄux cholesterol from
macrophages at the vascular wall that is redirected to the liver where it
is catabolized, we next analyzed the ability of ApoA-I amyloidogenic
variants to catalyze cholesterol eﬄux from J774 macrophages.
Macrophages were loaded with 3H-cholesterol, pre-incubated with
Cpt-cAMP to induce the expression of ABCA1 and incubated with either
lipid free (LF) or lipid bound (LB) proteins as acceptors of cholesterol,
in concentration- and time-dependent experiments. As shown in Fig. 7,
although the amyloidogenic variants (both LF or LB states) seemed to
have a lower eﬄux capacity (low Bmax, Fig. 7e and f), they were found
to have a higher eﬃciency (low Kd) to eﬄux cholesterol compared to
the WT protein (Fig. 7c and d). In particular, the L174S and L178H
variants showed the highest eﬃciency with a decrease in the Kd of 79%
and 64% at 4 h, in their LF state (Fig. 7c, right panel), and of 42% and
33% at 4 h and 60% and 55% at 24 h in their LB state (Fig. 7d, middle
and right panel) compared to WT (in LF and LB states, respectively).
Also, in the LF state, the L75P variant displayed a higher eﬄux eﬃ-
ciency at 4 h of eﬄux compared to WT protein (40% decrease in the Kd
for LF L75P compared to the native LF protein), while in the LB state,
the L75P showed a higher eﬃciency (64% decrease in Kd, compared to
the WT) only in the 24 h eﬄux (Fig. 7d, right panel). Finally, although
the G26R variant was not signiﬁcantly diﬀerent from the WT protein in
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their LF state, it showed a signiﬁcant higher aﬃnity in the eﬄux ana-
lyses (31% decrease in the Kd compared to WT) when lipid bound
(Fig. 7d, right panel). It is also worth to notice that the L174S and
L178H variants were more eﬃcient in catalysing cholesterol eﬄux from
macrophages compared to the other variants, especially when the eﬄux
was carried out for 4 h.
The DMPC (14:0) lipids provide the important advantage that for-
mation of the protein-lipid complexes can be assayed in real-time at
physiological-like buﬀer conditions without the need for solubilizing
detergents. However, lipids such as POPC (16:0) better mimics mam-
malian phospholipid compositions thus better resembling the physio-
logical HDL particles. The eﬄux capacity of ApoA-I amyloidogenic
variants in complex with POPC was therefore analyzed.
POPC-ApoA-I particles were produced by incubating the re-
combinant proteins with POPC at a 1:80 protein to lipid ratio and a
protein concentration of 0.5 mg/ml. The formed POPC rHDLs were then
analyzed by native gel electrophoresis (Fig. 8a) and, as in the case of
DMPC-bound proteins, the particles formed by the L174S and L178H
variants were smaller with respect to those containing the WT protein,
G26R and L75P variants, conﬁrming that the position of the mutation in
the ApoA-I sequence contribute to unique structures of the formed
rHDLs.
POPC-ApoA-I HDL were tested for their ability to remove choles-
terol from J774 macrophages (Fig. 8b). As already observed for DMPC-
ApoA-I rHDL, POPC-ApoA-I particles formed by the amyloidogenic
variants were all found to be more eﬃcient at catalysing cholesterol
eﬄux, at both time points analyzed. L174S and L178H showed the
highest eﬃciency (Fig. 8c) with a Kd reduction of 79% and 82% at 2 h
and 79% and 76% at 4 h, compared to the POPC particles formed by the
WT protein. However, diﬀerently from what observed in the case of
DMPC bound proteins, also the POPC particles formed by G26R and
L75P variants were characterized by a very high eﬃciency in removing
cholesterol from macrophages, showing a Kd reduction of 68% and 58%
at 2 h and 59% and 64% at 4 h, compared to the POPC-ApoA-I particles
formed by the native protein.
4. Discussion
The hallmark of ApoA-I hereditary systemic amyloidosis is the
progressive accumulation of protein ﬁbrils in the extracellular space of
target tissues, a mechanism that leads to organ dysfunction and failure
[2–4]. In addition, subjects aﬀected by this pathology show low plasma
levels of both the native and the amyloidogenic variant and a peculiar
lipid proﬁle, characterized by low levels of HDL and HDL-cholesterol
[18–22]. Nevertheless, despite this unfavourable lipid proﬁle, carriers
of ApoA-I amyloidogenic mutations do not show an increased risk of
CVD, suggesting that a compensative, protective mechanism may exist
[22]. To explore the structural and functional features of ApoA-I
amyloidogenic variants responsible for the clinical phenotype, we chose
four ApoA-I amyloidogenic variants representative of the two 3D hot-
spot mutation sites deﬁned in the X-ray structure of the C-terminal
truncated version of protein [27], with the G26R and L75P being lo-
cated in the N-terminal hot spot region (residues 26–107) and the
L174S and L178H in the hot spot region encompassing residues
154–178 [28].
We clearly demonstrate, as previously reported only for the WT
protein [38,39], that lipidation stabilizes and protects the amyloido-
genic variants from proteolysis. Indeed, the complementary proteolysis
experiments on LB proteins (Fig. 3b) showed a large reduction in the
number of cleavage sites compared to LF samples (Fig. 3a), suggesting
that the presence of lipids largely increases ApoA-I variants proteins
stability. This ﬁndings are also supported by the higher E:S ratios used
for the LB proteins in comparison with the respective LF forms. We also
demonstrate that the presence of an amyloidogenic mutation in ApoA-I
sequence represents a risk factor able to shift the equilibrium from a
lipid-bound towards a lipid-free conformation. Indeed, although all the
ApoA-I amyloidogenic variants were able to produce rHDL particles
both in vitro (Figs. 4, 5) and ex vivo (Fig. 6), they showed a signiﬁcant
decreased aﬃnity for lipids, with L174S and L178H with the lowest
lipid binding aﬃnity. Moreover, proteolytic cleavages were still ob-
served close to the mutation site (R26 and R27 in G26R, R173 in L174S
and L178H), conﬁrming that the presence of the mutation alters the
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local conformation of the protein. Consistent with our results, by using
a hydrogen-deuterium exchange approach, Das and co-workers found
that L170P and L159R ApoA-I variants were characterized by a high
solvent accessibility and caused the largest lipoprotein destabilization,
compared to W50R, G26R and F71Y variants [17].
The DLS and native gel analyses on rHDL (Fig. 1b) showed that the
lipoparticle formed by the L174S and L178H variants had a smaller size
with respect to those produced by G26R and L75P variants and SRCD
analyses revealed that L174S- and L178H-rHDLs were characterized by
a higher α-helical content (Fig. 1d, right panel). The diﬀerence ob-
served between the two classes of variants are not surprising if we
consider that the C-terminal domain of ApoA-I is characterized by the
highest hydrophobicity and it is known to mediate the binding to lipids
and to initiate the formation of HDLs [40,41]. Therefore, the presence
of mutations in close proximity to the protein C-terminus could desta-
bilize this domain and alter its interaction with lipids, conferring to the
variants a lower ability to form lipoparticles.
The analysis of the ApoA-I proteins in their LF form also revealed
interesting diﬀerences among the variants and the native protein. SRCD
data obtained at increasing protein concentrations (Fig. 1c and d) in-
dicate that, although the conformation and oligomeric state of the
variants are dependent on protein concentration, as demonstrated for
the native protein [42], the degree of structural rearrangements could
be inﬂuenced by the position of the mutation in the protein sequence.
Indeed, the C-terminal domain of ApoA-I is known to participate in the
self-association of the protein, as demonstrated by the inability of the
deletion mutants 185–243 and 209–243 to form oligomers in solution
[43]. The EPR analyses conducted on the native protein also supported
this hypothesis, identifying the C-terminal domain as the most sensitive
to molecular crowding [42]. Thus, the destabilization of the C-terminal
imposed by the presence of mutations might be responsible for the
impeded conformational change observed in the variants.
LF ApoA-I amyloidogenic variants also showed a higher suscept-
ibility to proteolysis compared to the native protein, in agreement with
our previous reports [13,14,17]. The higher susceptibility of all ApoA-I
variants in the region close to the mutation sites suggested an increase
of local ﬂexibility and exposure to solvent and indicates that all single
point mutations result in a large destabilization of the four-helix bundle
motif [28,44]. In addition to proteolytic cleavages close to the mutation
site, all the variants were characterized by an enhanced susceptibility in
both N- and C-termini and in the region encompassing residues
131–153. Notably, all these regions have also been described to have a
role in the HDL formation. In particular, Pollard and co-workers have
recently conﬁrmed that the N- and C-terminal domain of ApoA-I par-
ticipate in the process of lipidation and their destabilization slow down
the rHDL formation and demonstrated that the ﬂexibility and the
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opening of the central region of the protein is essential for the forma-
tion of the discoidal rHDLs [45].
Taken together, our results suggest that the decreased lipid aﬃnity
and the enhanced proteolytic susceptibility that characterize ApoA-I
amyloidogenic variants may explain the low ApoA-I and HDL plasma
levels observed in aﬀected carriers. Nevertheless, these observations are
in contrast with the cardiovascular state of ApoA-I amyloidogenic car-
riers, since the signiﬁcant reduction of ApoA-I and HDL levels should
imply a higher CVD risk. Our data on the ability of the ApoA-I amy-
loidogenic variants to eﬄux cholesterol from macrophages contribute
to explain this paradox. Indeed, all the ApoA-I variants, especially in
their LB state (either DMPC- or POPC-bound), showed a higher eﬃ-
ciency in catalysing the removal of cholesterol from macrophages
(Figs. 7 and 8). Surprisingly, the variants showing the lowest lipid
binding aﬃnity, L174S and L178H, were found to have the highest
eﬃciency in this process. We therefore hypothesize that the altered
conformations acquired by the mutated proteins stabilize the interac-
tion of the rHDL with ABCA1, thus enhancing the eﬄux of cholesterol
from macrophages. Another factor able to stabilize this interaction
could be represented by the amino acid substitution itself. This is also
suggested by studies on lipoparticles formation with ApoA-I cysteine
mutants in the presence of ABCA1-expressing HEK293 cells [45], where
the substitution of charged amino acids with cysteines dramatically
reduced the amount of HDL particles formation. In the same way, the
substitution of a hydrophobic amino acid with a polar or charged amino
acid, as in the case of L174S and L178H, could stabilize the binding
between the ApoA-I variant in the rHDL and ABCA1 on macrophages
cell surface.
The structural features here described for the amyloidogenic var-
iants are in line with previous reports on the R173C variant, also known
as Milano, an ApoA-I non-amyloidogenic variant [46] associated with a
decreased risk of CVD [47]. Indeed, in a structural and functional study,
Alexander and co-workers demonstrated that ApoA-I Milano was
characterized by a lower stability, lower aﬃnity for lipids and it was
able to give rise to HDL with a slightly smaller size [48]. Nevertheless,
Milano variant did not show any improved ability to eﬄux cholesterol
from macrophages suggesting that, in this case, the atheroprotection
observed in carriers of R173C is due to other factors than increased
cholesterol mobilization [49].
Although our studies show a connection between ApoA-I variants'
structural features and their ability to bind cholesterol, further experi-
ments will be carried out by using HDL particles isolated from patients
carrying these mutations in order to give strength to our ﬁndings and to
validate their biological relevance. In addition, while the SRCD and
limited proteolysis data provide important knowledge about protein
secondary structure, accessibility and stability, high-resolution 3D
structures of ApoA-I variants in nascent HDL are lacking. The de-
termination of such protein-lipid complexes is very challenging but
could potentially be resolved by using cryo-electron microscopy [50],
electron paramagnetic resonance spectroscopy [51] and/or X-ray
crystallography [27], thus giving new insights in the structure to
function properties of ApoA-I amyloidogenic variants.
5. Conclusions
The study shows that the position in the ApoA-I sequence of an
amyloidogenic mutation diﬀerently aﬀects both the protein aﬃnity for
lipids and the molecular structure of the formed HDL. Interestingly, the
amyloidogenic variants' reduced capability in forming HDL particles is
well compensated with a higher eﬃciency at catalysing cholesterol
eﬄux from macrophages. Our ﬁndings deﬁne the ApoA-I variants'
higher eﬃciency in the cholesterol eﬄux process as a protective me-
chanism able to compensate the unfavourable lipid proﬁle of patients
aﬀected by ApoA-I related amyloidosis, allowing us to provide ex-
planation to the paradox observed in the clinical phenotype.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2017.09.001.
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